

Effect of metformin and empagliflozin on myocardial function in insulin-resistant patients with heart failure: rationale and design of the METRIS-HF-DZHK18 trial

Conflicts of interests

Wolfram Doehner (Germany), Tim Friede (Germany), Frank Edelmann (Germany), Ulf Landmesser (Germany), Sebastian Winkler (Germany), Burkert Pieske (Germany), Fabian Knebel (Germany), Sebastian Kelle (Germany), Diethelm Tschöpe (Germany), Antje Meyer (Germany), Nadja Jauert (Germany), Marius Placzek (Germany), Jeanette Schulz-Menger (Germany), Stephan von Haehling (Germany), Stefan D. Anker (Germany)

WD: research support from the DZHK and consulting honoraria from Boehringer Ingelheim and other pharmaceutical companies outside the submitted work. All other authors declare no competing interests related to this manuscript.

TF: personal fees for statistical consultancies (including data monitoring committees) from Actimed, Apellis, Argenx, Aslan, AstraZeneca, Bayer, BerlinHeals, Boehringer Ingelheim, Biogen, Biosense Webster, BMS, Cardior, CSL Behring, Daiichi Sankyo, eCovery, Enanta, Fresenius Kabi, Galapagos, IQVIA, Johnson & Johnson, Novartis, PINK! gegen Brustkrebs, PPD, Priothera, RECARDIO, Recordati, Relaxera, Roche, Viatris, Vifor, VICO Therapeutics - all outside the submitted work.

FK: honoraria from AstraZeneca, Bayer, Boehringer, BMS, Novartis, GE Healthcare, Siemens Ultrasound, Canon Ultrasound, and other pharmaceutical companies outside the submitted work SK was supported by a grant from Philips Healthcare.

SK: grant from Philips Healthcare; funding from the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research), Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) -SFB-1470-B06 - all outside of the submitted work.

BP: advisory or speaker fees from AstraZeneca, Bayer, Novartis, Merck, Abbott.

SW: personal fees for consultancies from Biotronik and for scientific lectures from AstraZeneca, Boehringer Ingelheim, BMS, Daiichi Sankyo and Corvia, all outside the submitted work.

SvH: consultancy for and/or honoraria payments from AstraZeneca, Bayer, Besins Healthcare, Boehringer Ingelheim, BRAHMS, CSL Vifor, LumiraDX, MSD, Novartis, Novo Nordisk, Pfizer and Pharmacosmos and he reports research support from Amgen, Boehringer Ingelheim, IMI, and the German Center for Cardiovascular Research (DZHK).

SDA: grants from CSL/Vifor and Abbott Laboratories, and personal fees for consultancies, trial committee work and/or lectures from Actimed, Alleviant, Astra Zeneca, Bayer, Berlin Heals, BiMyo, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cardior, Cordio, Corvia, CSL/Vifor, CVRx, Cytokinetics, Edwards, Impulse Dynamics, Lilly, Mankind Pharma, Novo Nordisk, Occlutech, Pfizer, Pulnovo, Regeneron, Relaxera, Repairon, Scirent, Sensible Medical, Vectorious, Veru, Viscardia, Vivus, and V-Wave. Named co-inventor of two patent applications regarding MR-proANP (DE 102007010834 & DE 102007022367), but he does not benefit personally from the related issued patents.

All other authors report no conflicts of interest.